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Abstract
Background: Recently, it has been shown that increasing body mass index (BMI) in asthma is
associated with reduced exhaled NO. Our objective in this study was to determine if the BMI-
related changes in exhaled NO differ across asthmatics and controls, and to determine if these
changes are related to increased airway oxidative stress and systemic levels of leptin and
adiponectin.
Methods: Observational study of the association of BMI, leptin, and adiponectin with exhaled
nitric oxide (NO) and exhaled 8-isoprostanes in 67 non-smoking patients with moderate to severe
persistent asthma during baseline conditions and 47 controls. Measurements included plasma levels
of leptin, adiponectin, exhaled breath condensates for 8-isoprostanes, exhaled NO, pulmonary
function tests, and questionnaires regarding asthma severity and control.
Results: In asthmatics, BMI and the ratio of leptin to adiponectin were respectively associated with
reduced levels of exhaled NO (β = -0.04 [95% C.I. -0.07, -0.1], p < 0.003) and (β = -0.0018 [95%
C.I. -0.003, -0.00034], p = 0.01) after adjusting for confounders. Also, BMI was associated with
increased levels of exhaled 8-isoprostanes (β = 0.30 [95% C.I. 0.003, 0.6], p = 0.03) after adjusting
for confounders. In contrast, we did not observe these associations in the control group of healthy
non-asthmatics with a similar weight distribution.
Conclusion: In adults with stable moderate to severe persistent asthma, but not in controls, BMI
and the plasma ratio of leptin/adiponectin is associated with reduced exhaled NO. Also, BMI is
associated with increased exhaled 8-isoprostanes. These results suggest that BMI in asthmatics may
increase airway oxidative stress and could explain the BMI-related reductions in exhaled NO.
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Background
In recent years, there has been a parallel increase in the
prevalence of both asthma and obesity. This has led to the
speculation that increased BMI is a risk factor for asthma
[1]. Several cross sectional studies have shown higher
odds for developing asthma among obese children and
adults [2-5]; however, these studies were limited by their
inability to address the direction of this association, and
were susceptible to confounding factors [6]. Prospective
studies have shown that increasing BMI antedates the
diagnosis of asthma incidence and bronchial hyperre-
sponsiveness. This temporal pattern supports the idea that
obesity may actually cause versus simply associate with
asthma [7-11]. Further, obese asthmatics are also at
increased risk of having more severe respiratory symp-
toms, increased emergency room visits, and poor asthma
control [5,12-16]. The mechanisms by which obesity
increases asthma incidence or increases disease severity in
asthmatics are unknown.
Recent experimental data suggest that obesity-related
changes in adipokines could play a critical role in mediat-
ing airway inflammation and bronchial hyperresponsive-
ness (BHR) [6]. Leptin, an adipokine elevated in obesity
and known to induce satiety, has been shown to up-regu-
late various cytokines, promoting a state of chronic
inflammation [17]. Compared to saline treated mice, lep-
tin-infused mice had higher systemic IgE levels and
increased bronchial hyperresponsiveness only after oval-
bumin (OVA) inhalation [18]. In contrast, adiponectin,
which is reduced in obesity, and has anti-inflammatory
and antioxidant properties [19-21], has been shown to
reduce BHR and decrease airway inflammation following
OVA inhalation in mice [22]. However, whether or not
leptin and/or adiponectin can affect exhaled NO (nitric
oxide) levels and measures of airway oxidative stress in
asthmatics are unknown.
In a recent study, exhaled NO was inversely correlated
with BMI in subjects with asthma, yet a potential explana-
tion for this finding was not offered [23]. The purpose of
this study was to examine the association between BMI
and adipokines (leptin and adiponectin) with exhaled
NO in asthmatics and healthy controls, and to determine
whether BMI-related changes in exhaled NO can be attrib-
uted to changes in airway oxidative stress by measuring
exhaled 8-isoprostanes.
Methods
This study was conducted at Grady Memorial Hospital in
Atlanta, Georgia with the approval of the institutional
review board. Inclusion criteria included: participants 18
to 70 years of age, who were previously diagnosed with
moderate to severe persistent asthma (Global Initiative for
Asthma (GINA) class III – IV) [24] requiring treatment
with inhaled corticosteroids, ≥ 12% post-bronchodilator
increase in FEV1 (Forced exhalation volume in one sec-
ond) and a post-bronchodilator FEV1/FVC (Forced vital
capacity) ratio greater than 0.70. Exclusion criteria
included: current smokers, ex-smokers who stopped
smoking at least one year prior to study enrolment, or
total-life smoking history > 10 pack-year, and evidence of
other lung diseases or any other significant non-pulmo-
nary co-morbidities such as congestive heart failure with
ejection fraction < 50%, stable angina, chronic renal fail-
ure with serum creatinine > 2.0, documented cirrhosis,
other disorders requiring steroid treatment (vasculitis,
lupus, or rheumatoid arthritis), advanced cancer, or AIDS.
Subjects were also excluded if they had an asthma exacer-
bation during the month preceding enrolment.
Controls
From the hospital personnel, we recruited healthy, non-
asthmatics without any history of allergic diseases. The
controls were not active smokers, and met the same smok-
ing exclusion criteria used for the study population. Con-
trols were selected to match the gender, race, and weight
distribution of the study population.
Measurements
Height, weight, and waist to hip ratios were obtained in
all the participants. Participant's current level of asthma
severity was classified according to the 2004 GINA guide-
lines into mild intermittent (Class I), mild persistent
(Class II), moderate persistent (Class III), and severe per-
sistent (Class IV) asthma. Participants also completed the
Juniper asthma control questionnaire (ACQ)[25]. Atopy
was based on a positive or negative skin prick test docu-
mented in the clinic records. In all patients, obstructive
sleep apnea (OSA) and gastro-esophageal reflux disease
(GERD) were ascertained by either medical history or use
of medications to relieve GERD symptoms.
Exhaled NO was determined using an on-line continuous
chemiluminescence analyzer (CDL 88 sq Michigan, USA)
after overnight fasting following the American Thoracic
Society guidelines prior to spirometry [26]. Exhaled
breath condensate (EBC) was collected using the Rtube, a
non-invasive breath condensate collection device (Char-
lottesville, VA). To produce the condensate we used a
metal sleeve at an initial temperature of -10 Celsius, and
instructed subjects to breathe normally for 15 minutes
while using a nose-clip. After the collection session, the
samples were immediately stored in -70°C until analyzed.
Exhaled 8-isoprostanes were determined in duplicate
using an immunoassay (Cayman Chemical, Ann Arbor,
MI, USA) [27]. Pre and post-bronchodilator spirometry
were determined according to ATS guidelines [28]. Func-
tional residual capacity (FRC) was done using a nitrogen
gas dilution technique (CDL 88 sq Michigan, USA).Respiratory Research 2007, 8:32 http://respiratory-research.com/content/8/1/32
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In overnight fasting blood samples, we determined levels
of leptin and adiponectin. Adipokine levels were deter-
mined in duplicate using Luminex analysis (Linco
research Inc., St. Charles Missouri) [29].
Analysis
We used the Kruskal Wallis to compare non-normally dis-
tributed variables across BMI categories, and a t-test to
compare means between asthmatics and controls. The chi
square statistic was used to test the distribution of categor-
ical variables. We modelled the association of BMI and
adipokines (leptin, adiponectin, the leptin/adiponectin
ratio) with the log-normal of exhaled NO or exhaled 8-
isoprostanes using multivariable regression analysis. For
the asthma subjects, we adjusted the model for the follow-
ing potential confounders: age, gender, atopy, mean Juni-
per scores, degree of airflow obstruction (FEV1/FVC),
diagnosis of GERD, use of long-acting beta agonists, and
anti-leukotriene drugs. Given that all subjects with asthma
were taking inhaled corticosteroids, this medication was
not adjusted for in the model. Regression models were
checked for influential points, collinearity and distribu-
tion of residuals. Statistical analysis was done using SAS
9.1 (Cary, NC), a p< 0.05 was considered significant.
Results
Sixty-seven patients were recruited from the Asthma and
Allergy Clinic at Grady Memorial Hospital in Atlanta,
Georgia. The characteristics of the study population are
shown in table 1.
The majority of participants were females, African Ameri-
can, obese, and 70% had a positive skin test for allergens
documented in the clinic charts. Approximately a third of
the population were ex-smokers, although the average
amount of pack-years smoked was only 4. None of the
patients had evidence of significant chronic airway
obstruction. The mean post-bronchodilator FEV1 and FVC
percent predicted were respectively 73% (95% C.I. 70 –
79) and 81% (95% C.I. 75 – 86).
Clinical measures of asthma severity and control
The average Juniper score for asthma control was 2 (95%
C.I. 1.8 – 2.3). Although we observed a trend for higher
Juniper scores in overweight and obese subjects with
asthma, this difference was not statistically significant (p
= 0.2) (Figure 1). Moderate or severe persistent asthma,
based on the GINA score, was not more prevalent in obese
vs. non-obese participants (overall association of GINA
scores across BMI categories, p = 0.8) (Figure 2). All asth-
matics were taking an inhaled corticosteroid on a daily
basis; other medications included: 61% long-acting β-
agonists, 10% inhaled anti-cholinergics, 53% leukotriene
receptor blockers, 91% regular use of short acting β-ago-
nists, and 30% were taking combined therapy with long-
acting β-agonists and leukotriene receptor blockers.
Association of BMI with exhaled NO and exhaled 8-
isoprostanes
BMI was inversely associated with exhaled log-NO in uni-
variate (β = -0.04 [95% C.I. -0.06, -0.1; p < 0.003]) and
multivariate analysis (β = -0.04 [95% C.I. -0.07, -0.1; p <
0.003]), after adjusting for confounders. The correlation
between BMI and log-NO was r2 = -0.35 (p < 0.01). Also,
BMI was associated with increased exhaled 8-isopros-
tanes, in univariate (β = 0.22 [95% C.I. 0.04, 0.7; p =
0.03]) and multivariate analysis (β = 0.30 [95% C.I.
0.003, 0.6; p = 0.03]) after adjusting for the same covari-
ates. The correlation between exhaled 8-isoprostanes and
BMI was r2 = 0.33 (p = 0.03) and for exhaled 8-isopros-
tanes and log-NO the correlation was r2 = -0.16 (p = 0.2).
Figure 3 illustrates the association of log-transformed NO
and exhaled 8-isoprostanes with BMI in the asthmatics.
Association of leptin and adiponectin with exhaled NO 
and exhaled 8-isoprostanes
There were no significant associations between leptin or
adiponectin with exhaled log-NO; however, the ratio of
leptin (ng/ml) to adiponectin (μg/ml) (mean 0.0049
[95% C.I. 0.003–0.005]) was significantly associated with
exhaled log-NO in univariate (β = -0.00035 [95% C.I. -
0.002, -0.0003; p = 0.04]) and multivariate (β = -0.0018
[95% C.I. -0.003, -0.00034; p = 0.01]) analysis adjusting
for confounders. The correlation between the leptin/adi-
ponectin ratio and the log-NO was r2 = -0.28 (p = 0.04).
We did not observe significant associations between lep-
tin, adiponectin, and their ratio with exhaled 8-isopros-
tanes.
Comparison between asthmatics and the control 
population
A total of 47 controls were recruited for the study. Their
average age was 40 years (Range: 20 – 62) and was lower
than in the asthmatics (p < 0.01). The mean weight was
186 lb (95% C.I. 174 – 198) and 51% were obese, 78%
were female, and 88% were African American. These val-
ues did not statistically differ from the study population.
Compared to the asthmatics, controls had lower exhaled
NO levels (13 ppb [95% C.I. 10–15])(p< 0.01), higher
FEV1 (2.7 L [95% C.I. 2.5–3]), FVC (3 L [95% C.I. 2.8–3])
and FEV1/FVC ratio (0.86 [95% C.I. 0.8–0.9]), and similar
FRC (2.9 L [95% C.I. 2.5–3.3]). The levels of leptin (16
ng/ml [95% C.I. 12–20]) and adiponectin (31 μg/ml
[95% C.I. 28–35]) did not differ across groups, nor did
the levels of exhaled 8-isoprostanes (11 pg/ml [95% C.I.
8–13.8]).
In the controls, there was no significant association
between BMI with the log of exhaled NO (β = -0.001 [95%Respiratory Research 2007, 8:32 http://respiratory-research.com/content/8/1/32
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C.I. -0.02, 0.02; p = 0.9]), and exhaled 8-isoprostanes (β =
0.27 [95% C.I. -0.33, 0.88; p = 0.3]); also, there was no
significant association between the ratio of leptin/adi-
ponectin ratio with exhaled NO (β = -0.001 [95% C.I. -
0.02, 0.02; p = 0.9]). Figure 4 illustrates the linear associ-
ation of log-transformed NO and exhaled 8-isoprostanes
with BMI in the controls. The linear association of the lep-
tin/adiponectin ratio in subjects with asthma and the con-
trols is shown in Figure 5.
Discussion
This study evaluated the association of BMI and systemic
levels of leptin and adiponectin with levels of exhaled NO
and exhaled 8-isoprostanes in subjects with stable asthma
and healthy controls. In subjects with asthma, BMI and
the systemic leptin/adiponectin ratio were independently
associated with a reduction in exhaled NO, and BMI was
associated with increased levels of exhaled 8-isoprostanes.
In contrast, these associations were not observed in
healthy controls with a similar weight distribution. To our
knowledge, this is the first study describing the associa-
tion between BMI, leptin and adiponectin with exhaled
NO and exhaled 8-isoprostanes in adults with asthma and
in healthy controls.
Although there is compelling epidemiological evidence to
support an association between obesity and asthma, plau-
sible mechanisms for this association remain poorly
understood. It has been proposed that either obesity-
related changes in adipokines and/or the chronic systemic
inflammation in obesity, could lead to a parallel increase
in airway inflammation. Exhaled NO, a sensitive biomar-
ker of airway inflammation in asthma, would therefore be
expected to be higher in obese versus non-obese asthmat-
ics [6]. However, studies on BMI and exhaled NO do not
clearly support this assertion. Some studies have found a
positive correlation between BMI and exhaled NO in
healthy adults [30,31], whereas others have reported no
differences between obese and non-obese asthmatic chil-
dren [32]. In contrast, our results showed that exhaled NO
was inversely associated with BMI, after adjusting for
potential confounders in stable asthmatics. Our results are
similar to the findings from Barros et al, that showed a
negative association between BMI and exhaled NO (r2 = -
0.32 vs. r2 = -0.35 in our study) in 297 non-smoking asth-
matics with a mean BMI of 26 (95% C.I. 25.4 – 26.5) after
controlling for potential confounders [23]. The negative
association between BMI and exhaled NO does not neces-
sarily imply that increasing BMI leads to less airway
inflammation; it could imply however, that increasing
BMI could lead to changes in baseline airway NO redox
metabolism, through an increase in baseline airway oxi-
dative stress. In the presence of increased reactive oxygen
species, airway NO can be readily converted into reactive
Table 1: Characteristics of the study population
N6 7
Average age in years (Range) 48.9 (18 – 69)
Gender (% female) 83
White (%) 6
Black (%) 81
Other (%) 13
Ex-smokers n (%) 21 (33%)
Average Pack-per-year (95% C.I.) 4 (2 – 5)
Average body weight in pounds (95% C.I.) 198 (186 – 209)
Average BMI (95% C.I.) 32 (31 – 35)
Normal weight (BMI ≥ 18 ≤ 25) (%) 14
Overweight (BMI > 25 < 30) 28
Obese (BMI ≥ 30) 58
Average waist/hip ratio (95% C.I.) 0.87 (0.85 – 0.9)
Diabetes (%) 18
GERD treatment (%) 60
Hypertension (%) 45
Obstructive sleep apnea (%) 12
Average FEV1 (95% C.I.) 2.1 (2.0 – 2.3)
Average FVC (95% C.I.) 2.8 (2.6 – 3.0)
Average FEV1/FVC (95% C.I.) 0.80 (0.7 – 0.8)
Average FRC (95% C.I.) 3.2 (2.8 – 3.5)
Average Exhaled NO (95% C.I.) (ppb)* 25 (19 – 30)
Average Exhaled 8-isoprostanes (95% C.I.) (pg/ml) 11 (9.6 – 12.4)
Average Adiponectin (μg/ml) (95% C.I.) 3 (2.9 – 3.4)
Average Leptin (ng/ml) (95% C.I.) 15 (12 – 18)
BMI (Body mass index), FEV1 (Forced exhalation volume in one second), GERD (Gastro esophageal reflux disease), FRC (Functional Residual 
Capacity), Plasma adipokines were available for 50 asthmatics. Exhaled 8-isoprostanes were available for 56 asthmatics.Respiratory Research 2007, 8:32 http://respiratory-research.com/content/8/1/32
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nitrogen species (RNS) [33]. Because the total measured
exhaled NO is the end product of NO produced – NO
consumed, an increase in the RNS/NO ratio would result
in lower measured exhaled NO levels [34].
Our data support this hypothesis by showing a significant
association of BMI with exhaled 8-isoprostanes. Studies
have shown that asthmatics have higher levels of exhaled
8-isoprostanes than non-asthmatics, and that levels
increase with asthma severity [35-37]. In addition, BMI
has been associated with higher levels of plasma and uri-
nary levels of 8-isprostanes in men and women [38,39]. In
contrast to the inverse association between exhaled 8-iso-
prostanes and exhaled NO observed in our study, Mon-
tushi et al reported a positive correlation [37]; however,
this correlation was observed in only 12 mild asthmatics
that were not on inhaled corticosteroids, and was not
reported for patients with more severe disease that were
on inhaled corticosteroids; further, no data on body
weight was provided. It is possible that the association
between exhaled 8-isoprostanes with exhaled NO
changes, depending on whether or not this association is
determined during an asthma exacerbation or during
baseline conditions.
Alternatively, increasing BMI may lead to an increase in
airway oxidative stress via obesity-related changes in adi-
pokines. For example, Leptin increases proportionately
with BMI and has been shown to produce reactive oxygen
species (ROS) [40,41] through multiple mechanisms
including, endothelin-1 receptor activation, reduced Nic-
otine Adenine Dinucleotide (NAD(p)H) oxidase activa-
tion, and production of Tumor Necrosis Factor alpha
(TNF-α) [42-44]. Further, leptin levels in the bronchoal-
veolar lavage fluid are increased in obese mice models,
and instillation of leptin in the airway is associated with
acute lung injury in the presence of hyperoxia [45]. In
contrast, adiponectin is inversely associated with biomar-
kers of inflammation and with BMI [19,46], and low lev-
els of adiponectin have been associated with increased
systemic oxidative stress, and reduced NO production
from endothelial cells [47,48].
It is possible that the amount of oxidative stress necessary
to shift the airway redox balance towards conversion of
airway nitric oxide into RNS exists only when there is a
certain balance of leptin and adiponectin. For example,
obesity leads to increased leptin and reduced adiponectin;
this obesity-induced state of hyperleptinemia and
Distribution of asthma Juniper control scores by body mass index category Figure 1
Distribution of asthma Juniper control scores by body mass index category.Respiratory Research 2007, 8:32 http://respiratory-research.com/content/8/1/32
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hypoadiponectinemia is associated with increased sys-
temic inflammation and oxidative stress [46,49]. It is
therefore possible that reaching a certain threshold of
obesity-related systemic oxidative stress also results in
increased airway oxidative stress. In our study, the ratio of
leptin to adiponectin was not associated with exhaled lev-
els of 8-isoprostanes, which may be indicative that other
adipokine-independent pathways exist in increasing BMI-
related airway oxidation.
This study has some important limiting features. First, the
majority of our study population was African American,
female, either overweight or obese, and previously diag-
nosed with moderate to severe disease. These characteris-
tics may limit the external validity of our study,
particularly since women appear to be more susceptible to
obesity-mediated increase in asthma severity or asthma
incidence [1]; further, these results may not apply to asth-
matics with milder forms of asthma severity. Second,
determination of causation is impossible and determina-
tion of specific mechanisms is difficult in an observational
study design. Our results do provide a mechanistic
hypothesis by which obesity relates to asthma; however,
these results cannot provide information as to why obes-
ity increases the risk for asthma incidence. Third, using
questionnaires to evaluate conditions such as obstructive
sleep apnea and GERD has a lower sensitivity; therefore,
our results could be affected by residual confounding
from these misclassified co-morbid conditions. We have
to also consider that un-measured confounders, including
a more detailed assessment of glycemic control might
have important effects on the magnitude of both systemic
and airway oxidative stress. Fourth, due to the fact that
asthmatics were on several inhaled medications, it is diffi-
cult to determine the extent these medicines affected our
results. Though all asthmatics were on inhaled corticoster-
oids, the various dosages and the variable effects they may
have on individual patients may confound our results.
However, in the study by Barros et al [23], the association
between BMI and exhaled NO was not attenuated when
adjusting for inhaled corticosteroids. Further, in the 4-
state U.S. National Asthma Survey (NAS) the proportion
Global Initiative for Asthma scores for asthma severity by body mass index Figure 2
Global Initiative for Asthma scores for asthma severity by body mass index. [See additional file: figure keys].Respiratory Research 2007, 8:32 http://respiratory-research.com/content/8/1/32
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Association of exhaled nitric oxide and exhaled 8-isoprostanes by body mass index in adults with asthma Figure 3
Association of exhaled nitric oxide and exhaled 8-isoprostanes by body mass index in adults with asthma. [See 
additional file: figure keys].
Association of exhaled nitric oxide and exhaled 8-isoprostanes by body mass index in healthy non-asthmatic adults Figure 4
Association of exhaled nitric oxide and exhaled 8-isoprostanes by body mass index in healthy non-asthmatic 
adults. [See additional file: figure keys].Respiratory Research 2007, 8:32 http://respiratory-research.com/content/8/1/32
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of asthmatics using ICS is not higher among the obese. In
the NAS the use of inhaled corticosteroids among 1059
normal weight asthmatics was 28%, compared to 30% in
985 overweight and 34% in 1015 obese subjects with
asthma (p = 0.09) (unpublished observation) [50]. Fifth,
plasma adipokines and exhaled 8-isoprostane levels were
only available in 50 and 56 out of 65 patients respectively,
and could be a potential source of bias; however, we
would expect this bias to be small if any, as the absence of
these biological samples was not systematic, and was a
consequence of random patient refusal. Sixth, although
obese and overweight subjects had higher mean Juniper
ACQ, we were not able to detect meaningful differences in
asthma severity across BMI categories, given the size of
patient population; however, our intention was to mini-
mize differences in asthma severity across BMI categories,
to assure that the association between BMI and airway
biomarkers were not biased by differences in asthma
severity. Seventh, our study is limited by determining air-
way oxidation stress using 8-isoprostanes using a com-
mercial EIA kit which, although this method is highly
specific and has been validated by gas chromatography,
there have been contradictory results in the reproducibil-
ity of this essay [51].  Further; we did not explore other air-
way biomarkers of inflammation and reactive nitrogen
species. Finally, we did not assess directly the atopy status
in the controls, and are therefore unable to determine
how underlying atopy affected the comparison of NO
across adults with and without asthma.
Conclusion
In summary, this study shows that in asthmatics, in the
absence of an exacerbation, BMI and the leptin/adiponec-
tin ratio are associated with reduced exhaled NO, and BMI
is associated with increased exhaled 8-isoprostanes, possi-
bly reflecting an increase in baseline airway oxidative
stress. It remains to be elucidated whether these BMI-
related changes in airway oxidation, which were deter-
mined during baseline conditions, can be associated with
increased bronchial hyperresponsiveness and increased
asthma severity. Because these associations were not
observed among the controls, our results suggests that
BMI alone is not sufficient to produce airway changes in
airway NO and airway oxidative stress. Overall, these find-
Association of the ratio of serum leptin and serum adiponectin with the log of exhaled NO in subjects with asthma and con- trols Figure 5
Association of the ratio of serum leptin and serum adiponectin with the log of exhaled NO in subjects with 
asthma and controls. [See additional file: figure keys].Respiratory Research 2007, 8:32 http://respiratory-research.com/content/8/1/32
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ings provide important hypothesis-generating informa-
tion in understanding how obesity associates with asthma
severity.
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